| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
1 Harvard-Partners Center for Genetics and Genomics and 2 Rodent Histopathology Core, Harvard Medical School; 3 Department of Pathology, Tufts University Schools of Medicine and Veterinary Medicine, Boston, Massachusetts
Requests for reprints: Melanie H. Kucherlapati, Harvard-Partners Center for Genetics and Genomics, Harvard Medical School, 77 Avenue Louis Pasteur, New Research Building 160B, Boston, MA 02115. Phone: 617-525-4438; Fax: 617-525-4435; E-mail: mkucherlapati{at}rics.bwh.harvard.edu.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
In addition to cell cycle progression, Rb is now thought to be involved in many cellular processes, including irreversible exit from the cell cycle, protection from apoptosis, induction of cell typespecific gene expression, maintenance of the postmitotic state, and orderly progression through differentiation (5). Knockout mice for Rb provide direct evidence that the classic tumor suppressor protein plays a role in terminal differentiation of multiple tissue types. Rb/ mice die during E13 to E15 days of gestation and do not develop erythroid, neuronal, and lens tissue to their fully differentiated state (6, 7). Heterozygous mice succumb to pituitary tumors and medullary carcinomas of the thyroid earlier on a mixed genetic background than on C57Bl6 background (8). Chimeric mice, designed to rescue embryonic lethality of the Rb/ mice, develop a complex phenotype, such as pituitary tumors, medullar carcinoma of the thyroid (9, 10), and adrenal pheochromocytomas (11, 12).
The Rb pathway is implicated in the initiation of several tumor types. Its role, if any, in the progression of colorectal cancer is not defined. Mutations in Rb are not found in human gastrointestinal tumors. Rb mouse models do not develop colorectal cancer. To examine the effects of Rb as a modifier in colorectal cancer, we crossed the conditional Rb model Rbtm2Brn/ (13) with a Villin-Cre transgenic mouse [Tg(Vil-Cre); ref. 14] before the addition of an adenomatous polyposis coli (Apc) mutation that is known to initiate gastrointestinal tumorigenesis. Villin is an actin-binding protein that contributes to the assembly of the microvillus bundle (15). In adult mice, this gene is expressed specifically in the intestinal epithelium and kidney proximal tubules. The specificity of the promoter in adult tissues has led to its use in Cre recombinase transgenic mouse models (16). Cis-acting sequences necessary to drive the Villin promoter have been studied by several groups (1719). The model used in these studies has a 9-kb fragment that drives Cre gene expression. Embryonic expression of Villin is found in primitive endoderm, gut, nephros anlagen and its derivatives in the developing embryo, and extraembryonic visceral endoderm of the yolk sac (14). It is not known to be active in nonepithelial cells at any stage of development (20, 21).
We report here that Rbtm2Brn/Tg(Vil-Cre) mice have a significant decrease in survival rate and succumb to an unusually malignant and metastatic tumor phenotype at age
1 year. All mice observed developed pituitary tumors. Ninety percent of observed Rbtm2Brn/Tg(Vil-Cre) mice developed medullar carcinoma of the thyroid concurrent with pituitary tumors. Tumors from the thyroid have rearranged Rb and metastasized to many sites, including the stomach, small intestine, salivary glands, liver, lung, kidney, pancreas, spleen, bone marrow, fat, lymph nodes, dorsal root ganglion. More than half of the animals developed hyperplasia of pulmonary neuroendocrine cells. There was a low penetrance of adenocarcinoma of the lung derived from type 2 pneumocytes.
None of the animals had primary intestinal tumors, although some had stomach hyperplasia, and one had an unusual stomach tumor arising from a secretory gland. A mild predisposition for liver tumors was found, including adenocarcinoma of the bile duct and hepatoma with bile duct hyperplasia. Steatitis was observed with low frequency in the abdominal fat and in one case with a lipoma. Heterozygous animals also exhibited the tumorigenic phenotype, although the median survival of these animals and their wild-type siblings was not significantly different. Molecular analysis revealed some rearrangement of the floxed allele in almost all tissues tested and corresponding decrease in wild-type Rb RNA and protein levels in intestinal tissue.
| Materials and Methods |
|---|
|
|
|---|
Rbtm2Brn Tg(Vil-Cre) genotyping and identification of the rearranged allele. Offspring were genotyped routinely by PCR amplification as described previously (13). DNA was made from tail clippings of animals at 10 days old using DNeasy kits (Qiagen, Valencia, CA). Primers used for amplification were Rb212(149A) (5'-GAAAGGAAAGTCAGGGAATTGGG-3'), Rb18(149C) (5'-GGCGTGTGCCATCAATG-3'), and Rb19E(149B) (5'-CTCAAGAGCTCAGACTCATGG-3'). Reactions were carried out in a total of 25 µL. Reactions consisted of 0.05 units/µL Taq Gold Polymerase, 1x Taq Gold Buffer, 1.5 mmol/L MgCl2, 0.2 mmol/L deoxynucleotide triphosphate (dNTP), 0.4 µmol/L of each primer, and 25 ng DNA substrate. The PCR cycling profile consisted of 1 cycle at 94°C for 9 minutes; 35 cycles at 94°C for 30 seconds, 58°C for 30 seconds, and 72°C for 50 seconds; and 1 cycle at 58°C for 5 minutes. PCR products were analyzed on 3% agarose gels. Primers Rb19E(149B) and Rb18(149C) yield a 283-bp fragment that represents the unrecombined RbLOXP allele and a 235-bp fragment that represents the wild-type Rb allele. Primers Rb212(149A) and Rb18(149C) yield a 260-bp fragment from the recombined Rb
19 allele and a 600-bp fragment from the wild-type Rb allele. They were also used to detect rearrangement in the DNA from various tissues and tumors made using DNeasy kits.
RNA isolation and reverse transcription-PCR. RNA from tissue samples was isolated using a RiboPure kit (Ambion, Austin, TX) according to kit instructions. Tissue samples were snap frozen in liquid nitrogen at the time of dissection and stored in a cryogenic freezer. RNA was quantitated by 260 per 280 readings from a spectrophotometer (NanoDrop, Wilmington, DE). Reverse transcription-PCR (RT-PCR) was done using the SuperScript One-Step RT-PCR with Platinum Taq System (Invitrogen, Carlsbad, CA). Actin primers (5'-GGTCACCCACACTGTGCCCATCTACG-3' and 5'-GGATGCCACAGGACTCCATGCCCAG-3'; 0.2 µmol/L final concentration) were used for an internal control, and Rb primers (exon 18, 5'-CCTTGAACCTGCTTGTCCTC-3' and exon 20, 5'-GAAGGCGTGCACAGAGTGTA-3'; 0.2 µmol/L final concentration) were used to amplify from cDNA. Reactions were set up as suggested in the kit insert (1x Reaction Mix, 10 ng/µL RNA substrate, 0.4 units/µL Ambion's SUPERase In, 1 µL reverse transcriptase/Platinum Taq Mix; 50 µL total volume). PCR cycling conditions were 1 cycle at 50°C for 30 minutes and 94°C for 2 minutes; 35 cycles at 94°C for 15 seconds, 56°C for 30 seconds, and 72°C for 30 seconds; and 1 cycle at 72°C for 5 minutes and at 4°C.
Identification of the Villin-Cre transgene. The presence of the Villin-Cre transgene was identified by PCR amplification with specific primers for the Villin promoter (163F, 5'-GTGTGGGACAGAGAACAAACCG-3') and Cre recombinase gene (163R, 5'-TGCGAACCTCATCACTCGTTGC-3'). Reactions were carried out in 25 µL using 0.05 units/µL Taq Gold Polymerase, 1x Taq Gold Buffer, 1.5 mmol/L MgCl2, 0.2 mmol/L dNTP, 0.4 µmol/L primer, and 25 ng DNA substrate. The PCR cycling profile consisted of 1 cycle at 94°C for 9 minutes; 35 cycles at 94°C for 1 minute, 58°C for 45 seconds, and 72°C for 30 seconds; and 1 cycle at 58°C for 5 minutes. A diagnostic fragment of
900 bp obtained from the DNA of a founder mouse was isolated and eluted from a 1% agarose gel using a QIAquick gel extraction kit and sequenced to identify definitively the presence of Villin sequences adjacent to Cre recombinase.
Generation of survival curves. Birth and death dates for animals were recorded routinely. Prism software by GraphPad was used to generate survival curves. Villin-Cre-positive animals were observed as one cohort, and Villin-Cre-negative animals were observed as a second cohort for purposes of comparison.
Histopathologic analysis. Animals were euthanized by CO2 asphyxiation with subsequent cervical dislocation. Tissues were inspected on gross dissection and fixed in Bouin's fixative solution (RICCA Chemical Co., Arlington, TX). Organ samples were removed, embedded in paraffin blocks, and sectioned (5 µm) serially for histopathologic analysis. Both normal and neoplastic materials were stained with H&E and examined to determine the presence of tumor material and degree of malignancy in all tissues. Some tissues were snap frozen at the time of dissection in liquid nitrogen for RNA and DNA analysis. In sections of small intestines that were used for DNA analysis, muscularis and mucosa were present.
pRb and calcitonin detection by immunohistochemistry. Rb (M-15):sc-1538, a polyclonal antibody to a peptide mapping at the COOH terminus of murine pRb, was purchased (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Sections of intestine from Rbtm2Brn/Tg(Vil-Cre) and C57Bl6 were baked at 60°C for 1 hour. Paraffin was removed from sections by four washes of xylene (4 minutes each). After hydrating through 100%, 95%, and 75% ethanol (5 minutes each) and rinsing with distilled water, endogenous peroxide was quenched with 3% H2O2 in methanol for 20 minutes. Antigen retrieval was accomplished by boiling sections in sodium citrate buffer [10 mmol/L (pH 6.0)] for 25 minutes. Slides were washed in PBS for 10 minutes, and nonspecific antigen sites were blocked using 1% normal horse serum in PBS for 30 minutes. Primary antibody Rb (M-15):sc-1538 was applied to slides (1:50, 1:100, and 1:250 dilutions) and incubated at room temperature overnight in a humidity chamber. Affinity-purified biotinylated anti-goat IgG (H+L) (Vector Laboratories, Inc., Burlingame, CA) was used as secondary antibody (1:75 dilution) and applied for 1 hour at room temperature. A Vectastain Elite ABC kit (Vector Laboratories) was used as recommended in the package insert for antibody detection. The chromogen used for visualization was 3,3'-diaminobenzidine tetrahydrochloride. Mayer's hematoxylin solution (Sigma-Aldrich, St. Louis, MO) was used for counterstaining. Slides were coverslipped with Permount mounting solution (Fisher, Fairlawn, NJ).
Calcitonin (G-18):sc-7784, an affinity-purified goat polyclonal antibody raised against a peptide mapping at the NH2 terminus of calcitonin of human origin and cross-reactive with mouse calcitonin, was purchased (Santa Cruz Biotechnology). Tissue sections containing C-cell metastases were stained for calcitonin by the method described above for Rb immunohistochemistry.
| Results |
|---|
|
|
|---|
|
|
|
|
50%) with medullar carcinoma of the thyroid had metastases to distant sites, including the stomach (Fig. 2B), small intestine, lung, liver, kidney, pancreas, spleen, fat, lymph nodes, salivary gland, dorsal root ganglion, and bone marrow. The estimate of animals with metastases at 50% is probably somewhat low. Metastases were identified on inspection of H&E-stained sections, and representative metastases [stomach (Fig. 2C), fat, and small intestine] were later confirmed to be calcitonin positive by immunohistochemical staining. The lungs of 12 Rbtm2Brn/Tg(Vil-Cre)-positive animals were examined, and 7 were found to have hyperplasia of pulmonary neuroendocrine cells in addition to thyroid and pituitary tumors (penetrance, 58%). Four of 12 (33%) animals had C-cell metastasis to the lung (Table 2). One (8%) animal had an adenocarcinoma derived from type 2 pneumocytes.
Two Rbtm2Brn/Tg(Vil-Cre) mice had tumors involving the liver (penetrance, 17%; Table 2): one with an enlarged gall bladder that was proven to be an adenocarcinoma of the bile duct (1 cm in diameter) and the other with a hepatoma (with necrosis; 1 cm in diameter) with bile duct hyperplasia. Another two mice showed C-cell metastasis to the liver (17%). Two mice had steatitis in abdominal fat (17%), and one had a lipoma (penetrance, 8%).
Eight moribund Rbtm2Brn+/Tg(Vil-Cre) animals were examined histologically (Table 1). Four exhibited aggressive medullar carcinoma of the thyroid similar to Rbtm2Brn/Tg(Vil-Cre) siblings. C-cell metastases to the liver, kidney, lung, fat, testis, and salivary gland were observed in mice (29%). Pituitary tumors were found in 3 of 7 (43%) animals. Primary neuroendocrine hyperplasia of the lung was found in heterozygotes (14%). Wild-type animals did not have pituitary tumors. One succumbed to an aggressive undifferentiated sarcoma with metastasis to the liver and a primary benign lung tumor. None of the Rbtm2Brn Tg(Vil-Cre) homozygous or heterozygous mice had intestinal tumors. One (8%) animal developed an unusual stomach tumor that seemed to arise from a gastric secretory gland. Hyperplasia of the stomach was observed in Rbtm2Brn Tg(Vil-Cre) homozygous mice (30%).
The conditional Rb allele is rearranged in Rbtm2Brn/Tg(Vil-Cre) mice. Tissue sections from eight mice with histologic data and one mouse without histologic data were analyzed on a molecular level for rearrangement of the conditional Rb allele. Efficient rearrangement was observed in stomach, small and large intestines, kidney, spleen, and tumor DNAs (Fig. 1C). Wild-type Rb allele was detected at low levels in addition to an unexpected PCR amplification product (
489 bp). Abnormal PCR amplification products have been reported previously by other groups using the Rbtm2Brn mouse (26). Because they are not present in Southern analysis, they are thought to be artifacts.
Almost all tissues showed low levels of Rb
19 rearrangement. Extra gastrointestinal samples tested included kidney, lung, thyroid, pituitary, liver, spleen, heart, fat, eyes, reproductive organs, salivary gland, brain, tumor tissue, and tail. DNA from lung, heart, eyes, reproductive organs, and salivary glands amplified preferentially the wild-type allele (estimate made on a visual basis). Five of six thyroids with large tumors had complete rearrangement of the Rb
19 allele. One thyroid with a tumor had both normal and deleted alleles, and one thyroid had no rearrangement and tumor. Tested liver, fat, and brain tissues had approximately equivalent ratios of wild-type to rearranged allele. Two liver tumors had complete rearrangement of the Rb
19 allele.
We also tested for rearrangement of the Rb
19 allele in tail DNA sampled when the mice were 10 days old. Tail clippings from 15 Villin-Cre-positive mice were found to be wild-type, heterozygous, or homozygous for the Rb allele. Rb was rearranged in low levels in all tail DNA from recessive animals and to a lesser extent in tail DNA from all heterozygous animals (Fig. 1C). One of the homozygous animals seemed to have significantly more rearranged DNA than the other four mice. The Rb
19 allele was not rearranged in tail DNA from wild-type siblings.
The Villin-Cre transgene is intact in Rbtm2Brn/Tg(Vil-Cre) mice. PCR data showed that the Villin-Cre construct is intact in the Rbtm2Brn/Tg(Vil-Cre) mice. To confirm these data, the fragment amplified using a forward primer specific for the Villin promoter and a reverse primer specific for Cre recombinase was gel purified and sequenced. Villin promoter and Cre recombinase sequences were identified from the fragment confirming the mouse contained the transgene.
Rb
19 RNA detected in gastrointestinal, kidney, and tumor tissue. RNA isolated from tissues stored in liquid nitrogen was reverse transcribed. PCR fragments amplified using primers from exons 18 and 20 on cDNA substrate from a C57Bl6 mouse (exon numbering; ref. 13) yielded an appropriate size fragment for all observed tissues. That fragment was absent in RT-PCR from a Rbtm2Brn/Tg(Vil-Cre)-positive mouse in intestinal and liver tumor tissues (Fig. 1D) and in its place was a 108-bp fragment of predicted size from the Rb
19 allele. Liver and kidney tissues judged normal on gross inspection and amplified normal PCR fragments. Normal lung tissue from the same animal yielded an appropriate size fragment for wild-type allele.
Rbtm2Brn/Tg(Vil-Cre) mice do not have intestinal pRb. Immunohistochemical staining of intestinal sections of Rbtm2Brn/Tg(Vil-Cre) mice showed clearly an absence of pRb when compared with sections of C57Bl6 mice in almost all cells along the crypt villus axis (Fig. 3A ). In some sections, the tips of the villi had trace amounts of pRb staining. C-cell metastases from the small intestine, stomach, and fat also showed an absence of pRb staining confirming the Rbtm2Brn/ genotype of the medullary carcinoma tumors.
|
| Discussion |
|---|
|
|
|---|
We identify a latent tumor phenotype in Rbtm2Brn/Tg(Vil-Cre) mice at 12 to 17 months old. Ectopic rearrangement of the Rb gene leads to generation of aggressive tumors of the pituitary, medullary thyroid, liver, and bile duct as well as to hyperplasia of pulmonary neuroendocrine cells. The Rbtm2Brn mouse has been used previously in a p53-deficient background to produce "preneoplastic" lesions using intrabronchial injection of recombinant adenovirus-expressing Cre recombinase and is suggested to be a particularly good model for small cell lung carcinoma (29, 30). Because lung tumors develop in Rbtm2Brn/Tg(Vil-Cre) mice without preplanned removal of p53, comparative analysis may offer interesting insights. A low-penetrance tumor phenotype is seen for adipose tissue and squamous epithelium of the oral cavity. We found that observed C-cell tumors, C-cell metastases, and liver tumors have functionally lost the wild-type Rb allele, RNA, and/or pRb. We conclude that these tumors are the result of Cre-mediated rearrangement of the Rbtm2Brn allele. These results suggest that Villin-Cre is expressed in these tissues or in their precursors during embryogenesis. Embryonic Villin expression has been reported in the primitive endoderm, gut, nephros anlagen and its derivatives, and extraembryonic visceral endoderm of the yolk sac (14). In the adult mouse, its expression is limited to the epithelial cells of the digestive and urogenital tracts (21). It is not known to be active in nonepithelial cells at any stage of development (20, 21). However, low levels of Villin transcripts have been found in liver and pancreas primordia, and the pattern of Villin expression in the adult liver and pancreas suggests that it is not expressed in epithelial cells, such as hepatocytes and pancreatic acinar cells, but is expressed in biliary and pancreatic duct cells (18). These observations correlate with the low-penetrance phenotype seen in Rbtm2Brn/Tg(Vil-Cre) mice of adenocarcinomas and hyperplasia of the bile duct. Because C cells become malignant in response to Rb rearrangement, we suggest the Villin promoter may be active during embryogenesis in neural crest or neural crest stem cells, the progenitor cells of the medullar thyroid. Such expression of the Villin gene has not been documented previously.
"Illegitimate" Villin transcripts have been found in normal bone marrow (31). Cre production in bone marrow followed by circulation of hematologic cells that contain the rearranged allele may explain the presence of low levels of rearranged Rb
19 allele in tissues not expected to have Villin promoter activity during embryogenesis, such as tissue precursors for spleen, heart, and tail.
Some Cre constructs [e.g., Keratin 14 Cre (32)] have been shown to have recombinase expressed in oocytes, making transmission of the gene through males a necessity. We are unaware that Villin-Cre would have such constraints; however, to address the possibility, we assert that four of five founder Villin-Cre mice were male. Because subsequent offspring were intercrossed, if Villin is expressed in oocytes, Cre could have been expressed in the F2 generation. It is noteworthy in the Keratin 14 Cre model that early expression of Cre in oocytes leads to the complete deletion of all lox Pflanked sequences in all tissues of the offspring. Because there are tissues in Rbtm2Brn/Tg(Vil-Cre) mice that remain completely or predominantly unrearranged, we think it unlikely that expression of the Villin promoter in oocytes would account for the ectopic Villin expression observed in Rbtm2Brn/Tg(Vil-Cre) mice.
An interesting feature of these animals is the aggressive nature of the medullar carcinoma of the thyroids that were shown to have the ability to metastasize to unusual locations, including stomach, small intestine, liver, lung, kidney, pancreas, spleen, bone marrow, fat, salivary glands, lymph nodes, and dorsal root ganglion. Metastasis to the bone marrow and dorsal root ganglion is observed rarely in mouse models of cancer. Because there is a paucity of genetically engineered mouse models for metastasis, there has been a call for their development (33). Metastasis is modeled in mice in several different ways. Immune incompetent mice (e.g., nude and severe combined immunodeficient) have been used for transplantation studies involving syngeneic or xenogeneic tumor tissues. These approaches include tumor cell injection into the bloodstream and subcutaneous or transplantation of tumor material. These methods have various advantages and drawbacks. Theoretically, autochthonous tumors are more similar to tumor initiation and progression in humans. They permit the study of modifiers of tumor suppressors and oncogenes and in the presence of an intact immune system. We suggest that the Rbtm2Brn/Tg(Vil-Cre) model could offer insight into the process of metastasis for this reason. The ability of medullar carcinoma of the thyroid to metastasize to unusual locations must reflect significant genetic alterations in these cells. Identification of candidate genes involved in metastasis could be accomplished by microarray analysis of RNA from these tumors. Comparison of microarray expression and comparative genome hybridization patterns with patterns from human thyroid tumors known to contain Rb mutations could permit identification of novel genes involved in the human disease (34). Because medullar carcinomas of the thyroids become quite large (7-8 mm), relatively large quantities of tumor material would be available for screening.
| Acknowledgments |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank Dr. Mari Kuraguchi for the immunohistochemical staining procedure and Dr. Kenneth Hung for critically reading the article.
Received 7/31/05. Revised 1/ 4/06. Accepted 1/12/06.
| References |
|---|
|
|
|---|
20/+ mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 1994;9:10217.[Medline]This article has been cited by other articles:
![]() |
A. Cerrato, V. De Falco, and M. Santoro Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets J. Mol. Endocrinol., October 1, 2009; 43(4): 143 - 155. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Guo, S. Longshore, R. Nair, and B. W. Warner Retinoblastoma Protein (pRb), but Not p107 or p130, Is Required for Maintenance of Enterocyte Quiescence and Differentiation in Small Intestine J. Biol. Chem., January 2, 2009; 284(1): 134 - 140. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Kucherlapati, K. Yang, K. Fan, M. Kuraguchi, D. Sonkin, A. Rosulek, M. Lipkin, R. T. Bronson, B. J. Aronow, and R. Kucherlapati Loss of Rb1 in the gastrointestinal tract of Apc1638N mice promotes tumors of the cecum and proximal colon PNAS, October 7, 2008; 105(40): 15493 - 15498. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Mason-Richie, M. J. Mistry, C. A. Gettler, A. Elayyadi, and K. A. Wikenheiser-Brokamp Retinoblastoma Function Is Essential for Establishing Lung Epithelial Quiescence after Injury Cancer Res., June 1, 2008; 68(11): 4068 - 4076. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Saenz-Robles, J. A. Markovics, J.-L. Chong, R. Opavsky, R. H. Whitehead, G. Leone, and J. M. Pipas Intestinal Hyperplasia Induced by Simian Virus 40 Large Tumor Antigen Requires E2F2 J. Virol., December 1, 2007; 81(23): 13191 - 13199. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |